Funded Startups in Abingdon
Recent disclosed rounds in Abingdon span from 2026-06-30 (Biodexa Pharmaceuticals, $4M) back to 2021-05-12 (Summit Therapeutics, $75M), with the most recen…
Recent disclosed rounds in Abingdon span from 2026-06-30 (Biodexa Pharmaceuticals, $4M) back to 2021-05-12 (Summit Therapeutics, $75M), with the most recent 12 entries concentrated heavily in the last few years. The largest disclosed amount is Summit Therapeutics’ $75M round (2021-05-12), which dwarfs the next-largest disclosed amounts in this slice: $25M (Intralink, 2023-07-03) and $18M (Oxitec, 2022-04-13). In parallel, stage/disclosure is mixed: “Series Unknown” appears 5 times and “undisclosed” appears 2 times across the 12 rows.
The list also clusters by timing and sector. Three of the biotechnology entries (Biodexa Pharmaceuticals, Orthox Ltd., Summit Therapeutics) appear across 2021-05-12 to 2026-06-30, while multiple non-biotech rounds land in a mid-window from 2022-12-09 to 2023-07-03 (BelleVie $2M; Oxitec $18M; Sense Biodetection $15M; Intralink $25M). Sector-wise, Hardware has two entries (EnSilica and Infinitesima Ltd.), and the remaining single-entry sectors don’t repeat enough to form a dominant cluster beyond biotech and hardware.
Most recent rounds
12 shownRelated listings
Frequently asked
What stands out about the largest disclosed funding compared with the rest of the Abingdon entries shown?
Summit Therapeutics’ $75M (2021-05-12) is the only disclosed round in the $50M+ range, while the next-largest disclosed amounts are $25M (Intralink, 2023-07-03) and $18M (Oxitec, 2022-04-13). That gap makes the 2021-05-12 round an outlier versus the rest of the disclosed amounts in this 12-row slice.
How much of the list is concentrated in the most recent time window?
Five of the 12 rows are dated 2025-02-03 or later, led by Biodexa Pharmaceuticals’ 2026-06-30 close ($4M). The most recent year is thus populated more by smaller disclosed rounds (e.g., Zircotec $810K on 2026-04-09; EnSilica $13M on 2025-02-03) and undisclosed outcomes (Nexeon on 2026-05-28; Infinitesima Ltd. on 2026-01-22).
Is disclosure consistent here, or do “Series Unknown” and “undisclosed” obscure comparisons?
Of the 12 rows, 5 are labeled “Series Unknown” (e.g., Biodexa Pharmaceuticals 2026-06-30; Zircotec 2026-04-09; EnSilica 2025-02-03), and 2 additional entries have “undisclosed” amounts (Nexeon 2026-05-28; Infinitesima Ltd. 2026-01-22). This means most cross-company size comparisons rely only on the remaining disclosed amounts.
Which sectors appear repeatedly enough to form a pattern rather than single occurrences?
Biotechnology is the most repeated sector with three entries: Biodexa Pharmaceuticals ($4M on 2026-06-30), Orthox Ltd. ($12M on 2022-02-09), and Summit Therapeutics ($75M on 2021-05-12). Hardware follows with two entries (EnSilica $13M on 2025-02-03; Infinitesima Ltd. with an undisclosed amount on 2026-01-22).
Are there stage trends, or do stages vary widely across this slice?
Stage labels are split across categories, with “Series Unknown” showing up 5 times and “undisclosed” amounts showing up 2 times, limiting stage-to-size inference. Where stages are specified, the largest disclosed example is Summit Therapeutics’ unspecified stage label in the table with $75M (2021-05-12), while earlier specified rounds include Seed (BelleVie, $2M on 2022-12-09), Grant (Oxitec, $18M on 2022-04-13), and Series A/B examples like Orthox Ltd. ($12M, 2022-02-09) and Sense Biodetection ($15M, 2021-11-17).
Which entries look most anomalous by disclosed amount within the shown dataset?
Beyond the $75M outlier (Summit Therapeutics, 2021-05-12), the smallest disclosed amount is Zircotec at $810K (2026-04-09). The next step up after $810K is EnSilica at $13M (2025-02-03), with no disclosed amounts between roughly $810K and $13M in these 12 rows.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.